Q2 2026 13F · SEC CIK 1858703

Blue Owl Capital Holdings LP

Hedge fundFiled 2026-08-11 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $658.0M
Reported positions: 71
Top holdings a year, 3 yrs: +5.1%
Average holding period: 3 qtrs

Blue Owl Capital Holdings LP is a hedge fund that reported 71 positions worth $658.0M in its Q2 2026 13F, filed 2026-08-11. Its largest holdings were Space Ex Tech Spacex Class A (SPCX, 36.3%), Aktis Oncology Inc (AKTS, 15.0%), Cullinan Therapeutics Inc (CGEM, 4.3%). A portfolio copying its top holdings returned 5.1% a year over the last 3 years, against 20.4% for the S&P 500.

Blue Owl Capital Holdings LP holdings largest 50 of 71 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Blue Owl Capital Holdings LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
SPCXSpace Ex Tech Spacex Class A	36.3%	—	1,398,815	—	$239.0M
AKTSAktis Oncology Inc	15.0%	15.2%	3,070,219	-2.9%	$99.0M
CGEMCullinan Therapeutics Inc	4.3%	7.3%	1,539,764	-19.4%	$28.0M
LRMRLarimar Therapeutics Inc	4.2%	8.6%	9,163,157	+28.7%	$27.9M
NCDLNuveen Churchill Direct Lending Corp	4.0%	7.3%	2,143,626	+0.0%	$26.6M
MPLTMaplight Therapeutics Inc	4.0%	5.5%	729,929	-27.4%	$26.2M
COFCapital One Financial Corp	3.7%	—	119,757	—	$24.0M
OBDCBlue Owl Capital Corporation	3.4%	6.1%	2,045,070	+0.0%	$22.2M
FISNDeep Fission Inc	2.2%	—	1,333,333	—	$14.7M
DELLDell Technologies Inc	2.2%	0.6%	32,961	+137.1%	$14.2M
HLLYHolley Inc	1.7%	3.5%	4,376,888	+3.3%	$11.2M
EYPTEyepoint Pharmaceuticals Inc	1.7%	3.2%	762,594	-16.4%	$10.9M
SGMTSagimet Biosciences Inc	1.5%	0.5%	1,260,544	+277.5%	$9.7M
CRVSCorvus Pharmaceuticals Inc Com	1.4%	2.1%	608,600	+11.7%	$9.1M
ARTVArtiva Biotherapeutics Inc	1.3%	—	874,542	—	$8.5M
CMPXCompass Therapeutics Inc	1.2%	4.2%	3,624,076	+23.2%	$7.9M
CNDTConduent Inc	1.1%	1.7%	5,036,595	+0.0%	$7.4M
RYTMRhythm Pharmaceuticals Inc	1.0%	1.4%	61,455	+0.0%	$6.8M
CMPSCompass Pathways PLC	1.0%	—	450,000	—	$6.4M
RAREUltragenyx Pharmaceutical in	0.9%	1.7%	182,638	-39.7%	$6.1M
PVLAPalvella Therapeutics Inc	0.8%	1.0%	36,259	+16.0%	$5.5M
IMAImagenebio Inc	0.8%	1.3%	917,692	-4.3%	$5.4M
VRDNViridian Therapeutics Inc	0.7%	—	260,000	—	$4.8M
IMMXImmix Biopharma Inc	0.7%	1.3%	437,552	-20.1%	$4.5M
ORICOric Pharmaceuticals Inc	0.7%	0.5%	400,000	+166.7%	$4.3M
LENZLenz Therapeutics Inc	0.7%	1.2%	756,722	+49.3%	$4.3M
AQSTAquestive Therapeutics Inc	0.6%	1.5%	942,932	-30.0%	$3.9M
STWDStarwood Ppty Tr Inc Com	0.5%	0.7%	196,355	+23.8%	$3.2M
EVMNEvommune Inc	0.4%	0.6%	180,000	+80.0%	$2.4M
ELDNEledon Pharmaceuticals Inc	0.3%	1.2%	566,509	-60.1%	$2.2M
CABACabaletta Bio Inc	0.3%	—	714,710	—	$2.2M
CHYMChime Financial Inc.	0.3%	—	89,878	—	$1.8M
CNTXContext Therapeutics Inc	0.2%	3.6%	2,934,015	-42.3%	$1.6M
WWWw Intl Inc	0.2%	0.4%	84,399	-11.7%	$1.3M
MRKRMarker Therapeutics Inc	0.1%	0.2%	554,250	+0.0%	$815K
ADCTAdc Therapeutics SA	0.1%	0.7%	733,568	+0.0%	$785K
23256X407Cybin Inc	0.1%	—	59,911	—	$396K
FLDFold Hldgs Inc	0.1%	0.3%	856,632	+0.0%	$385K
654484153Niocorp Devs Ltd	0.1%	0.1%	268,280	-16.2%	$381K
RZLVWRezolve Ai PLC	0.0%	0.1%	235,121	+0.0%	$214K
BNAIWBrand Engagement Network Inc	0.0%	0.1%	1,453,808	-12.8%	$204K
PIPRPiper Sandler Companies	0.0%	0.1%	2,428	+0.0%	$176K
29286X119Engene Therapeutics Inc	0.0%	—	511,177	—	$148K
CELCCelcuity Inc	0.0%	—	1,249	—	$131K
USDEWStablecoinx Inc	0.0%	—	250,000	—	$103K
ETPCEnergy Transfer L P	0.0%	0.0%	5,326	+0.0%	$102K
CAICaris Life Sciences Inc	0.0%	0.0%	4,711	+0.0%	$84K
VODVodafone Group PLC	0.0%	—	5,371	—	$71K
23834J110Dave Inc	0.0%	—	28,750	—	$68K
MRNOMurano Global Invt PLC	0.0%	—	261,875	—	$63K

What Blue Owl Capital Holdings LP bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Added to

SGMT Sagimet Biosciences Inc+277.5% shares
ORIC Oric Pharmaceuticals Inc+166.7% shares
DELL Dell Technologies Inc+137.1% shares
EVMN Evommune Inc+80.0% shares
LENZ Lenz Therapeutics Inc+49.3% shares
LRMR Larimar Therapeutics Inc+28.7% shares
STWD Starwood Ppty Tr Inc Com+23.8% shares
CMPX Compass Therapeutics Inc+23.2% shares

Reduced

ELDN Eledon Pharmaceuticals Inc-60.1% shares
CNTX Context Therapeutics Inc-42.3% shares
RARE Ultragenyx Pharmaceutical in-39.7% shares
AQST Aquestive Therapeutics Inc-30.0% shares
MPLT Maplight Therapeutics Inc-27.4% shares
IMMX Immix Biopharma Inc-20.1% shares
CGEM Cullinan Therapeutics Inc-19.4% shares
EYPT Eyepoint Pharmaceuticals Inc-16.4% shares

Left the top 50

ENGN enGene Holdings Inc.was 8.1%
Compass Pathways PLCwas 1.4%
CVEO Civeo Corp Cdawas 1.3%
KALV Kalvista Pharmaceuticals Incwas 1.2%
OVID Ovid Therapeutics Incwas 1.1%
PLRX Pliant Therapeutics Incwas 1.0%
Larimar Therapeutics Incwas 0.5%
Engene Holdings Incwas 0.3%

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +20.0% /yr; S&P 500 +20.1%
3 years: +5.1% /yr; S&P 500 +20.4%
5 years: +4.2% /yr; S&P 500 +15.9%

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$658.0M	71
Q1 2026	$372.2M	74
Q4 2025	$324.0M	78
Q3 2025	$322.1M	72
Q2 2025	$309.9M	72
Q1 2025	$310.1M	73
Q4 2024	$434.0M	78
Q3 2024	$515.8M	132
Q2 2024	$359.6M	41
Q1 2024	$500.6M	44
Q4 2023	$418.3M	42
Q3 2023	$129.3M	15

Questions about Blue Owl Capital Holdings LP's portfolio

What stocks does Blue Owl Capital Holdings LP own?

Blue Owl Capital Holdings LP's latest 13F, for Q2 2026 and filed Aug 11, 2026, lists 71 positions worth $658.0M. The largest are Space Ex Tech Spacex Class A (SPCX) at 36.3%, Aktis Oncology Inc (AKTS) at 15.0%, Cullinan Therapeutics Inc (CGEM) at 4.3%, Larimar Therapeutics Inc (LRMR) at 4.2% and Nuveen Churchill Direct Lending Corp (NCDL) at 4.0%.

What did Blue Owl Capital Holdings LP buy last quarter?

In Q2 2026, Blue Owl Capital Holdings LP added Sagimet Biosciences Inc (SGMT) (+277.5% shares), Oric Pharmaceuticals Inc (ORIC) (+166.7% shares) and Dell Technologies Inc (DELL) (+137.1% shares), compared with its Q1 2026 filing.

What did Blue Owl Capital Holdings LP sell last quarter?

In Q2 2026, Blue Owl Capital Holdings LP cut from its top 50 enGene Holdings Inc. (ENGN), cut from its top 50 Compass Pathways PLC, cut from its top 50 Civeo Corp Cda (CVEO), cut from its top 50 Kalvista Pharmaceuticals Inc (KALV), cut from its top 50 Ovid Therapeutics Inc (OVID), Eledon Pharmaceuticals Inc (ELDN) (-60.1% shares), Context Therapeutics Inc (CNTX) (-42.3% shares) and Ultragenyx Pharmaceutical in (RARE) (-39.7% shares), compared with its Q1 2026 filing.

How has Blue Owl Capital Holdings LP's portfolio performed?

A portfolio copying Blue Owl Capital Holdings LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +5.1% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +20.0% against +20.1%. Over 5 years: +4.2% a year against +15.9%.

When is Blue Owl Capital Holdings LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Blue Owl Capital Holdings LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.